Directory · FI
Biotechnology Research in Finland
A register of firms and the professionals working at them in the Biotechnology Research sector based in Finland. Browse the public index, then filter or export on Kipplo.
Companies
125 on file
Roche Finland
Roche kehittää innovatiivisia lääkehoitoja ja diagnostisia testejä tarjotakseen potilaille enemmän aikaa läheistensä kanssa. Yhdessä yhteistyökumppaneidemme kanssa olemme mukana ratkaisemassa terveydenhuollon haasteita, edistämme parempaa hoitoa ja kehitämme hoitopolkuja varhaisesta diagnoosista aina yksilöityyn lääkehoitoon. Roche on globaali lääkealan ja diagnostiikan edelläkävijä. Suomessa Roche toimii kahtena eri yrityksenä. Diagnostiikasta vastaa Roche Diagnostics Oy ja lääkeliiketoiminnasta Roche Oy. Päivitämme tälle LinkedIn-sivulle molempien yritysten kuulumisia. Terveydenhuolto on merkityksellistä meille kaikille. Siksi työskentelemme varmistaaksemme, että innovaatiomme olisivat nopeasti saatavilla kaikille niitä tarvitseville suomalaisille potilaille yhteiskunnan resurssien näkökulmasta kestävällä tavalla. Roche sijoittaa vuosittain yli 20 % globaalista liikevaihdostaan tutkimus- ja tuotekehitystoimintaan. Näin varmistamme valmiudet yhä uusiin tieteellisiin, diagnostisiin ja digitaalisiin harppauksiin syöpätautien ja hematologisten sairauksien, keskushermostosairauksien ja silmätautien aloilla. Yhdistämällä yksilöityä diagnostiikan ja lääkekehityksen osaamista pyrimme nopeuttamaan uusien, potilaiden hoitoa mullistavien ratkaisujen kehittämistä. Tämä tavoite tekee meistä sen mitä olemme. Se tekee meistä Rochen. Lisätietoja löydät osoitteesta
10001+ staff
Kcl
KCL offers a unique, open access pilot and laboratory scale environment for testing, production, scale-ups, demonstrations activities in a centralized site. KCL is an ideal platform for developing existing products and processes. It also serves as an innovative new product developer derived from furthering the science of pulp, paper and board. Biomaterial based new products can be found and developed through complete utilization of KCL’s advanced equipment and expertise. KCL provides an infrastructure where customers’ own ideas and equipment can be tailored and fitted into the process. Our in-depth knowledge and expertise is included in the services we provide our customers. We serve all customers with the highest degree of integrity and confidentiality.
11 to 50 staff
Metgen
We design and market novel enzymatic solutions for the most challenging of industrial conditions to meet our customers need. MetGen’s enzymes – MetZyme® – are industrial, highly-active, natural catalysts that accelerate chemical reactions. They can survive in harsh industrial environments which enables novel applications and combination with other enzymes. MetGen products are protected by international patents. Offering customized projects to meet customer’s specific needs, MetGen uses advances in genetic engineering and microbiology to adapt enzymes to harsh industrial conditions and to handle a variety of lignocellulosic substrates. MetGen has achieved successful industrial trials with sector leaders in the forest and renewable chemicals. In 2014 MetGen Oy has won the Best in BioFuel / BioEnergy category for the Global Cleantech Cluster Association (GCCA) 2014 Later Stage Award. The GCCA’s Global Top 10 Winners represent the best of the association’s 52 member clusters and over member companies.
11 to 50 staff
Admescope
Admescope, part of the Symeres organization, is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor-made services to drug discovery in the area of ADME-Tox. Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right level of research can always be found for the customer whether in the discovery or lead optimization phase. All of the services include comprehensive study consulting which enables tailoring the study according to customers’ specific needs. The state-of-art quality data is ensured by optimizing the conditions according to the compounds instead of using generic protocols. All of the data can be interpreted for the customer and helped to understand the real meaning of the numerical values and observations. Since 2020, Admescope has been part of Symeres, having capabilities to provide medicinal chemistry and integrated drug discovery and development services via the broader Symeres organization. Service Offering • in vitro Metabolism • in vivo DMPK • Drug Interactions • Quantitative Bioanalysis • Permeability & Transporters • Physicochemistry & Binding • in vitro Toxicology • Biologics • Integrated medicinal chemistry and drug discovery services via Symeres organization
51 to 200 staff
Biohit Oyj
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. Product range consists of products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. Acetium innovation is developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. We are looking for distributors and licencing partners.
11 to 50 staff
Genevia Technologies
Genevia Technologies is a Finnish CRO specialized in delivering diverse bioinformatics solutions. The company was founded in 2011 as a spin-off enterprise by a group of computational systems biology researchers from Tampere University of Technology, in Tampere, Finland. Over a course of 15 years, our team has built up an extensive experience in analyzing and integrating various microarray, next-generation sequencing and proteomics data. We have also been developing and applying systems biological and mathematical modeling techniques on a wide range of applications from bacterial metabolomics to genomics of human cancers. Our mission is to facilitate the use of high-throughput genetic measurements and biological big data in life science companies and research institutions. We provide general genomics and bioinformatics consultation, support in experimental design, acquisition of cost-effective experiments, analysis and integration of data, and design of custom data analysis and visualization pipelines that organizations can use to analyze their data independently. You can find more information about our company, services and customers on our website at
11 to 50 staff
Uniogen
Uniogen is specialized in cancer diagnostics, molecular and immunoassay diagnostics of infectious diseases, and laboratory instrumentation. We are targeting the diagnostics market with new, innovative solutions under development for early cancer detection in central laboratories, and in various laboratory and decentralized healthcare settings.
51 to 200 staff
Linio Biotech
Linio Biotech is an R&D company developing a category defining regenerative injectable for natural tissue augmentation, leveraging our proprietary Tience® technology. Our goal is to create a paradigm shift in aesthetic medicine by replacing temporary fillers and invasive procedures with a safe, injectable, and biologically active product that regenerates soft tissue — naturally and sustainably. Tience® technology is already in commercial use in the Nordics and supported by clinical research and real-world data. Now, we’re taking that foundation and applying it to a new indication with global potential.
11 to 50 staff
Resistomap
Resistomap is committed to tackling one of the most pressing global health challenges: antimicrobial resistance (AMR). Founded in 2018 and based in Finland, we specialize in providing environmental surveillance services for antibiotic resistance, offering cutting-edge solutions to monitor and map the presence of resistance genes in various ecosystems, including wastewater, soil, and other environments. Using state-of-the-art molecular techniques like the SmartChip Real-Time PCR system, we deliver precise data that empowers our customers—including academic institutions, government bodies, and private companies worldwide—to understand and mitigate the spread of AMR. As a global service provider, our mission is to support efforts across the globe in combating antibiotic resistance and promoting sustainable antibiotic use through data-driven insights.
11 to 50 staff
Labmaster Ltd
Labmaster Ltd develops innovative solutions for clinical and veterinary diagnostics and research. Labmaster LUCIA™ is a point-of-care immunoassay platform based on patented cathodic electrochemiluminescence (LM-CECL) technology. It enables fast, accurate and affordable human & veterinary diagnostics including human CRP, MxA, equine SAA, equine IgG kits and many more in the pipeline. We work in a positive, international work culture with determined and motivated people. Our work is driven by our strong belief in the LM-CECL technology and the possibilities it can offer to mainstream healthcare. As a fast-paced organization working hard to create quality products that meet the IVD regulatory requirements, it is ever more important that we pay attention to the positive energy at our workplace. In this effort, our work community acknowledges every team member with their unique skills and ideas. Efforts, achievements and milestones don’t go unnoticed at Labmaster.
11 to 50 staff
Medicortex Finland Oyj
Medicortex Finland Oyj is a biotechnology company dedicated to developing diagnostics and treatments for acute neurodegenerative conditions, including traumatic brain injury (TBI) and concussion. The company is currently focusing on the development of a rapid test, based on a proprietary biomarker, for detection of TBI and concussion. Medicortex was founded by Dr. Adrian Harel in Turku, Finland, in 2014 and it operates as a public limited company. Dr. Harel has a track record in business management and leadership of early-stage biotechnology companies- Kuvaus suomeksi: Medicortex Finland Oyj on bioteknologian alan yritys, joka on keskittynyt parantamaan tapaturmaisten aivovammojen (TBI) diagnostiikkaa ja hoitoa. Yrityksen nykyinen painopiste on kehittää biomerkkiaineisiin perustuvaa diagnostiikkaa, jolla pystytään arvioimaan aivovamman laajuutta ja vaikeusastetta.
1 to 10 staff
Nordic Bioproducts Group Ltd
Nordic Bioproducts Group Oy ("NBG”), founded in 2019 as a spin-off from Aalto University, stands at the forefront of cellulose innovation, bioproduct development, and commercialization in the Nordics. At the heart of its mission is a commitment to optimizing the use of renewable natural resources while reducing the world’s dependence on fossil-based resources, fostering circular solutions, and catalyzing impactful change on a global scale. As a pioneering force, the company is dedicated to introducing breakthrough technologies and biomaterials that redefine the landscape of sustainable solutions. We help industries to combat the effects of global warming with innovative and environmentally friendly bioproducts and bioproduction technologies while generating great economic value. The bigger the scale, the better for the environment. We have technology and equipment fully ready for implementation, offering a fast track to market with bioproducts and biotechnologies.
11 to 50 staff
Protectpipe
Luonnollinen ratkaisu viemäriputkien ongelmien ennaltaehkäisyyn ProtectPipe on suomalainen mikrobiteknologiayritys, joka tuottaa innovatiivista ratkaisua, joka poistaa orgaanista jätettä viemäriputkista. Liuoksen sisältämät mikrobit kirjaimellisesti syövät putkistoon kertyvän orgaanisen jätteen. Kun orgaaninen jäte poistuu putkista, se ei pääse mätänemään ja muodostamaan syövyttävää rikkihappoa. Näin putkien eroosio vähenee ja käyttöikä pitenee. Samalla vältytään voimakkaiden viemärinavauskemikaalien käyttämiseltä ja päätymiseltä ympäristöön. Lue lisää osoitteessa
1 to 10 staff
Reagena Oy
Reagena is a biotechnology company developing, manufacturing and selling internationally proven, high quality products for healthcare laboratories, industry and pharmacies. Reagena’s core competencies include: • Development of award-winning immunological point-of-care tests and enzyme immunoassays for diagnosing infectious diseases such as lyme, tick-borne encephalitis and hantavirus • Production of reagents, staining solutions, buffers and fixatives for life sciences and industry • Execution of contract manufacturing and product development services • Distribution of leading diagnostics brands in the Nordic region Reagena products are manufactured in Toivala, Finland, according to ISO 9001 and ISO 13485 certified quality management systems. Read more at
11 to 50 staff
Tilt Biotherapeutics Ltd
TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com
11 to 50 staff
City-Lab Oy
City-Lab Oy is a privately-owned Finnish life science customer service company. We offer personal service near end-users and provide the customer with laboratory supplies, chemicals and equipments from our collaborating companies. We streamline the whole ordering process. We help customer identify their needs and compare the options available within our product portfolios. We handle technical enquiries, quote requests and provide product information in co-operation with the technical specialists. We are glad to offer multiple alternatives to our customers as many wish to compare their options. Our up-to-date information about the products, techniques, best prices and campaigns help our customer arrive to well-thought purchase decisions without wasting valuable research time. We manage the ordering process and keep track of the deliveries. We receive and handle shipments, recycle packing materials and store the products at correct temperatures for as long as needed. In case of problems, we also handle the product reclamations, invoicing corrections and other troubles the customers might face during the process. The customer enjoys all this service with no delivery fees or other extra expenses for both directly received products as well as back-orders. There is no need to buy products in big bulks or combine orders, but the customers can order whatever and whenever needed. A big part of the appeal for the customer to use City-Lab is based on the local warehouse that is constantly refined according to customers’ requirements and preferences. Our broad spectrum of suppliers covers nearly all fields of laboratory sciences, which practically makes us a onestop-shop. In the modern days of online shopping baskets and virtual service, the face-to-face customer service with familiar people and on the-spot deliveries are highly valued. In City-Lab we represent companies that share the ideologies of high quality products and customer-oriented service.
1 to 10 staff
Genomill
Genomill is unlocking the true potential of NGS for everyday healthcare with Geno1®, a radically rethought sequencing library preparation based on circular DNA and PCR-free workflows. It combines hybrid-capture–like performance with amplicon-level simplicity: targeted sequencing with minimal steps and the fastest turn-around time compared to other commercial tests. This simplicity makes sequencing faster to run, easier to automate, and practical even in low-infrastructure environments. By enabling decentralized sequencing without compromising sensitivity or scalability, Geno1® changes how next-generation sequencing can be applied in real-world healthcare. Find out more at
11 to 50 staff
Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients. Herantis is listed on the Nasdaq First North Growth Market Finland.
11 to 50 staff
Nordshield
NORDShield offers bio-based anti-odor and antimicrobial textile treatment solutions that improve product performance and the end-user experience
11 to 50 staff
Valo Therapeutics Ltd
Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.
11 to 50 staff
Labema Group
Founded in 1988, Labema is a Life Science and Biotechnology expert organization, that imports, promotes and delivers first class diagnostic equipment and supplies to healthcare, food industry, and research laboratories. Labema’s main expertise areas are Microbiology, Molecular biology, Food diagnostics and Drug of Abuse diagnostics. Labema’s operations are strongly based on scientific and practical expertise in diagnostic systems and processes with a focus to understand and anticipate customers’ constantly changing needs. Labema’s permanent market assessment and close partnership with customers and suppliers are the keys to its success.
11 to 50 staff
Medisapiens Ltd
MediSapiens creates cutting-edge solutions for transforming biomedical data into knowledge, insight, and value, especially with the help of genomic data. Our mission is to help our partners transform reactive and collective healthcare into proactive and personalized healthcare through better use and combination of data. Our key offering is the MediSapiens Genomics Suite, that integrates genomic data as part of your operations. We are based in Helsinki, Finland and Cambridge, United States. For more information, please visit: https://medisapiens.com/ and follow us at @MediSapiens
11 to 50 staff
Rnacious Laboratory
Why should we care about tRNA modification? Transfer RNA (tRNA) is at the heart of translation — the process at which the genetic code of an organism is deciphered into functional machines, i.e. proteins. In this process, the tRNA molecules work as adapters that proof read the code and, upon a successful match, add the correct amino acids, i.e. the building blocks that make up proteins. For this intricate process to function correctly, tRNA molecules need to be chemically modified at key positions of the molecule. This is achieved by specialised tRNA modification enzymes acting alone or as part of complex pathways. These chemical modifications provide structural integrity to the tRNA molecule and more importantly, they regulate the accuracy and speed of translation. Despite their crucial role in a core function of life, we are only beginning to understand the vast implications of tRNA modification and the complexity of the underlying mechanisms. We know that in single-celled eukaryotes, such as yeast, tRNA modifications are seldom required when the growth conditions are optimal. However, once a yeast cell lacking proper tRNA modification encounters any form of stress, severe problems in stress response systems, protein homeostasis, etc. start to emerge. The more complex the organism, the more severe the implications. In humans, a fault in only one mitochondrial tRNA modifying enzyme gives rise to severe developmental disorders, as manifested in the MERFF and MELAS syndromes. Problems in amino acid charging of tRNA molecules causes neurodegenerative diseases, such as ALS. Moreover, incorrect regulation of tRNA modification enzymes has been associated with breast cancer and various other forms of cancer
1 to 10 staff
Scellex
SCellex develops a lab method and research tool for spatial single cell sequencing directly from tissues and cells.
1 to 10 staff
